ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

Table 1 The basic characteristics of the inclusion studies

First Author	Year	Country	Tumor stage	Regimen of chemotherapy	Genotyping method	Nunber of cases	Resistant			Responder			P (HWE)	NOS score
First Author	Year	Country	Tumor stage	Regimen of chemotherapy	Genotyping method	Nunber of cases	CC	CT	TT	CC	CT	TT	P (HWE)	NOS score
Kang	2006	Korean	I-IV	platinum-based chemotherapy	Snapshot	60	15	5	0	20	16	4	0.763	8
Smith	2007	USA	I-IV	platium ± paditaxel chemotherapy	PCR–RFLP	176	11	22	15	23	60	45	0.701	8
Steffensen	2008	Danish	II-IV	carboplatin and cyclophosphamide combined-chemotherapy	TaqMan assay-based Real time PCR	100	3	7	2	12	34	42	0.239	8
Steffensen	2011	Danish	I-IV	Combined with carboplatin and paclitaxel	PCR–RFLP	157	2	4	7	15	71	58	0.321	8
Bösmüller	2011	Germany	I-III	Standard carboplatin-taxane	PCR–RFLP	41	6	5	3	7	9	11	0.098	8
Moxley	2013	USA	IIIB-IV	Platium- Based Chemotherapy	PCR–RFLP	64	10	13	9	14	8	10	0.005	8
Qi BL	2013	China	I-IV	Platinum-based combination	Snapshot	220	38	26	9	78	67	2	0.003	7
Huo XY	2017	China	I-IV	TP (paclitaxel / docetaxel + cisplatin / carboplatin / oxaliplatin)	PCR–RFLP	280	43	29	16	104	82	6	0.049	7
Yang SY	2017	China	III-IV	Cisplatin / carboplatin, combined with cyclophosphamide / paclitaxel	PCR–RFLP	209	28	31	12	70	67	1	0.000	7
Bao Y	2020	China	II-IV	cisplatin based Chemotherapy	PCR–RFLP	559	209	124	47	115	55	9	0.473	8

NOS Newcastle–Ottawa Scale, PCR–RFLP Polymerase chain reaction-restriction fragment length polymorphism, HWE Hardy–Weinberg equilibrium

ISSN: 1757-2215